根治性肾输尿管切除术作为上尿路尿路上皮癌伴区域淋巴结转移临床证据患者多模式治疗策略一部分的获益与危害:欧洲泌尿外科学会指南的系统综述与Meta分析
该系统综述与Meta分析纳入17项观察性研究,评估cN+期上尿路尿路上皮癌患者接受根治性肾输尿管切除术(RNU)作为多模式治疗一部分的肿瘤学与术后结局。诱导化疗联合RNU较单纯RNU与更高的病理降期、病理完全淋巴结缓解及更长的总生存相关,且未显著增加术后并发症。
要点
- 诱导化疗联合RNU较单纯RNU与更高的病理降期和病理完全淋巴结缓解相关。
- 诱导化疗联合RNU较单纯RNU与更长的总生存相关,且未显著增加术后并发症。
- 诱导化疗联合RNU较RNU联合辅助化疗或单纯化疗与更长的总生存相关。
核心结论
- 对于一般状况良好且可切除的cN+期上尿路尿路上皮癌患者,若对诱导化疗有反应,使用RNU可在不显著增加危害的情况下提供最大的肿瘤学获益。
研究设计与样本
- 按照系统综述与Meta分析首选报告条目指南,检索2000年1月至2024年9月发表的文献,纳入17项观察性比较与非比较研究。
- 研究对象为cTanyN+M0期上尿路尿路上皮癌患者,评估RNU作为多模式治疗策略一部分的肿瘤学或术后结局。
- 15项研究评估在RNU基础上加用化疗的效果,其中1项未具体说明给药时机、14项为诱导治疗、5项为辅助治疗;2项研究评估在化疗基础上加用RNU的效果。
主要发现
- 诱导化疗联合RNU与单纯RNU相比,病理降期的风险比(RR)为3.06(95%CI 2.48-3.77,p<0.001,I²=0%,p=0.44)。
- 诱导化疗联合RNU与单纯RNU相比,病理完全淋巴结缓解的RR为2.80(95%CI 2.03-3.86,p<0.001,I²=0%,p=0.47)。
- 诱导化疗联合RNU与单纯RNU相比,总生存的风险比(HR)为0.52(95%CI 0.42-0.64,p<0.001,I²=14%,p=0.33)。
- 诱导化疗联合RNU与单纯RNU相比,总体术后并发症的RR为1.14(95%CI 0.79-1.64,p=0.48,I²=0%,p=0.76),主要术后并发症的RR为0.48(95%CI 0.18-1.24,p=0.13,I²=0%,p=0.87)。
- 诱导化疗联合RNU与RNU联合辅助化疗相比,总生存的HR为0.58(95%CI 0.38-0.89,p=0.01);与单纯化疗相比,总生存的HR为0.49(95%CI 0.32-0.76,p=0.001,I²=46%,p=0.17)。
临床怎么用
- 作者认为,对于一般状况良好且可切除的cN+期上尿路尿路上皮癌患者,若对诱导化疗有反应,诱导化疗联合根治性手术可能是最佳的多模式治疗策略。
局限性
- 所有纳入研究均为观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Given the uncertainty regarding the role of radical nephroureterectomy (RNU) as part of a multimodal treatment strategy for upper tract urothelial carcinoma (UTUC) patients with cN+ disease, we aimed to perform a systematic review and meta-analysis of the corresponding literature. METHODS: Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 17 observational comparative and noncomparative studies, published between January 2000 and September 2024, evaluating UTUC patients with cTanyN+M0 disease (P) who received RNU as part of a multimodal treatment strategy (I), as compared with any treatment strategy if applicable (C), to assess oncological or postoperative outcomes (O). Meta-analyses were further performed, as appropriate. KEY FINDINGS AND LIMITATIONS: Overall, 15 studies evaluated the effectiveness of adding chemotherapy to RNU in the perioperative setting without specifying the exact timing of delivery (n = 1), in the induction setting (n = 14), or in the adjuvant setting (n = 5), while two studies evaluated the effectiveness of adding RNU to chemotherapy. Meta-analyses showed that the use of induction chemotherapy plus RNU versus RNU alone was associated with greater odds of pathological downstaging (risk ratio [RR] = 3.06; 95% confidence interval [CI] = [2.48-3.77]; p < 0.001; I2 = 0%; p = 0.44) and pathological complete nodal response (RR = 2.80; 95% CI = [2.03-3.86]; p < 0.001; I2 = 0%; p = 0.47) as well as prolonged overall survival (HR = 0.52; 95% CI = [0.42-0.64]; p < 0.001; I2 = 14%; p = 0.33) without any significant impact on the risk of overall (RR = 1.14; 95% CI = [0.79-1.64]; p = 0.48; I2 = 0%; p = 0.76) and major (RR = 0.48; 95% CI = [0.18-1.24]; p = 0.13; I2 = 0%; p = 0.87) postoperative complications. In addition, the use of induction chemotherapy plus RNU versus RNU plus adjuvant chemotherapy (HR = 0.58; 95% CI = [0.38-0.89]; p = 0.01) or chemotherapy alone (HR = 0.49; 95% CI = [0.32-0.76]; p = 0.001; I2 = 46%; p = 0.17) was associated with prolonged overall survival. Limitations include the observational design of all included studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of RNU could provide the greatest oncological benefits without any significant harm in selected UTUC patients with fit general condition and resectable cN+ disease responding to induction chemotherapy. PATIENT SUMMARY: In this report, we looked at the outcomes of radical surgery in combination with systemic chemotherapy for upper tract urothelial carcinoma with clinical evidence of dissemination to the surrounding lymph nodes. We observed that the use of radical surgery was associated with the greatest oncological benefits without any increased risk of postoperative complications in patients with fit general condition and resectable disease responding to induction chemotherapy. We conclude that the use of induction chemotherapy plus radical surgery could be the best multimodal treatment strategy for these patients.
引用
- Rai BP, Parmar K, Pradere B, et al. Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines. Eur Urol Oncol. 2025. PMID: 39779382. doi:10.1016/j.euo.2024.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。